Ensysce Biosciences



Partnership Overview



Our worldwide patent portfolio covers the TAAP and MPAR technology, with 45 issued patents globally, 30 pending and 17 issued US patents. Out-Licensing is an opportunity for non-US Opioid Abuse-Deterrent products & global ADHD Overdose Program.

Life Cycle Management

As proprietary schedule 3 & 4 drugs look to extend their patent and market positioning, abuse deterrent & overdose management are variables that can now be addressed while delivering a Prodrug solution. The benefit of a novel Prodrug NCE (new chemical entity) solution are the obtainable patent real estate in otherwise commoditized markets, lending to an extended proprietary market position.

Specialized Abuse Deterrent or Overdose Uses

As new drugs come to market that are shown to have addictive and/or abusive profiles, our technology can be applied to address those concerns while expanding a firm's product pipeline. The potential application of THC (Tetrahydrocannabinol) is a good example of a category of drugs that could benefit from TAAP and MPAR.


For Partnership Opportunities